Intracranial hemorrhage (ICH) is one of the most devastating bleeding complications associated with anticoagulation therapy. Approximately 7000 ICHs occur annually as a result of treatment with anticoagulants. Major risk factors are advanced age, elevated blood pressure (BP), intensity of anticoagulation, and previous cerebral ischemia. Combining aspirin and anticoagulants or antiplatelet agents also increases the risk of ICH. It is well known that careful monitoring of the international normalized ratio and avoidance of potentially dangerous drug combinations may make anticoagulation less risky. A review of the literature also suggests that modest BP reduction greatly reduces the risk of ICH. A study of patients with previous stroke or transient ischemic attack who were receiving antiplatelet agents or oral anticoagulants demonstrated a 50% decrease in stroke with a reduction of 9 mm Hg in systolic BP. A decrease of 76% was noted in patients who achieved systolic BP reductions of 12 mm Hg.
Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs